
Sign up to save your podcasts
Or


HRSA’s new 340B model will test a rebate model for 340B drugs, requiring providers to file for a rebate rather than receiving an upfront discount. The AMGA discusses the ramifications of this change, along with CMS’ plan to accelerate a repayment plan as part of its proposed outpatient rule.
By AMGA (American Medical Group Association)5
1010 ratings
HRSA’s new 340B model will test a rebate model for 340B drugs, requiring providers to file for a rebate rather than receiving an upfront discount. The AMGA discusses the ramifications of this change, along with CMS’ plan to accelerate a repayment plan as part of its proposed outpatient rule.

112,835 Listeners

56,541 Listeners

368,661 Listeners

9,198 Listeners

47,622 Listeners

57,794 Listeners

61,429 Listeners

10,056 Listeners